(Q44665303)

5 December 2017

title

Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression (English)

1 reference

5 December 2017

7

1 reference

5 December 2017

Vlachaki MT

1

1 reference

5 December 2017

Hagemeister FB

2

1 reference

5 December 2017

Fuller LM

3

1 reference

5 December 2017

Besa PC

4

1 reference

5 December 2017

Hess MA

5

1 reference

5 December 2017

Brown B

6

1 reference

5 December 2017

Cox JD

8

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 June 1997

1 reference

International Journal of Radiation Oncology Biology Physics

5 December 2017

published in

1 reference

5 December 2017

volume

38

1 reference

5 December 2017

issue

3

1 reference

5 December 2017

page(s)

593-599

1 reference

The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Clinical versus pathologic stage I and II Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Radiation therapy in clinical stage I and II Hodgkin's disease. The Princess Margaret Hospital Lymphoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Late relapse among patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Female Reproductive Potential after Treatment for Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Hodgkin's disease limited to intrathoracic sites

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

The role of radiation therapy in Hodgkin disease: experience and controversy. The 54th annual Janeway Lecture: 1989.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Radical treatment of Hodgkin disease with radiation therapy: results of a 15-year clinical trial. The 1985 Erskine lecture.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

The role of prognostic factors in treatment selection for early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Hodgkin's disease: study of treatment intensities and incidences of second malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

Risk of second cancers after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

An updated dose-response analysis in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900036-9

7 January 2021

10.1016/S0360-3016(97)00036-9

Identifiers

DOI

1 reference

5 December 2017

1 reference